Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Want to cut your energy bills? Here’s how five experts are doing it 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
 & Lead Plaintiff Deadline: July 11, 2017 - EconoTimes)
NEW YORK, May 25, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akari Therapeutics Plc (“Akari” or the “Company”) (NASDAQ:AKTX) and certain of its officers, on behalf of shareholders who purchased Akari securities between March 30, 2017 and May 11, 2017, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/aktx.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and specifically that: (1) Dr. Gur Roshwalb (“Roshwalb”), Akari’s Chief Executive Officer (“CEO”), and possibly others, caused false information about Akari to be published, including but not limited to, false information regarding the Phase 2 PNH trial of Coversin; (2) Akari lacked sufficient controls and protections to prevent such behavior; and (3) consequently, Akari’s financial statements were materially false and misleading at all relevant times.
According to the complaint, following an announcement made on May 11, 2017 that Akari’s CEO, Roshwalb, was placed on administrative leave while the Board of Directors investigates the involvement of Akari personnel related to a report issued on April 26, 2017, Akari stock dropped significantly.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/aktx or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Akari you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
